BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BioCentury | Nov 16, 2018
Company News

U.K. Parliament issues ultimatum to Vertex, NHS, NICE

In a last ditch effort to bring to a close a years-long fight over access to cystic fibrosis drugs in the U.K., a Parliament committee said it would release on Nov. 30 documents it has...
BioCentury | Nov 10, 2018
Company News

U.K. Parliament issues ultimatum to Vertex, NHS, NICE

In a last ditch effort to bring to a close a years-long fight over access to cystic fibrosis drugs in the U.K., a Parliament committee said it would release on Nov. 30 documents it has...
BioCentury | Jul 27, 2018
Company News

Vertex gives update on CF triple combos

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it expects to submit an NDA by mid-2019 for a triple combination therapy to treat cystic fibrosis. The company is evaluating two different triple combinations -- VX-445 or VX-659 plus...
BioCentury | Jul 25, 2018
Company News

Vertex gives update on CF triple combos, reports earnings

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Wednesday it expects to submit an NDA by mid-2019 for a triple combination therapy to treat cystic fibrosis. The company is evaluating two different triple combinations -- VX-445 or VX-659...
BioCentury | Jul 20, 2018
Company News

NHS makes 'final' offer to Vertex

David Ramsden, chief executive of the U.K.-based Cystic Fibrosis Trust, tweeted out a letter he received from NHS England that detailed what the agency said was its "final proposal" to Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) regarding...
BioCentury | Jul 17, 2018
Company News

Vertex responds to NHS’s ‘final’ offer

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it is evaluating a “final” offer from NHS England for the company’s cystic fibrosis drugs but is concerned the latest bid to break the stalemate between the parties falls short....
BioCentury | Mar 20, 2018
Company News

MPs call on U.K. government to resolve Orkambi impasse

Members of Parliament called on the U.K. government on Monday to resolve an impasse that has stalled reimbursement discussions between Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and NHS England over the price of Orkambi lumacaftor/ivacaftor. The move...
BioCentury | Sep 1, 2014
Strategy

Back to School 2014: Paying the piper

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug...
BioCentury | Feb 11, 2013
Company News

GlaxoSmithKline pharmaceuticals news

...America (PhRMA) said that releasing patient-level trial data is "irresponsible with potentially harmful consequences for future medicine...
Items per page:
1 - 10 of 16
BioCentury | Oct 17, 2019
Product Development

Horizon 2020’s successor aims for improved uptake of innovation

The European Commission is in the midst of creating Horizon Europe, the successor to Horizon 2020, and this time around it aims to do more to ensure technologies created through the program are advanced by...
BioCentury | Nov 16, 2018
Company News

U.K. Parliament issues ultimatum to Vertex, NHS, NICE

In a last ditch effort to bring to a close a years-long fight over access to cystic fibrosis drugs in the U.K., a Parliament committee said it would release on Nov. 30 documents it has...
BioCentury | Nov 10, 2018
Company News

U.K. Parliament issues ultimatum to Vertex, NHS, NICE

In a last ditch effort to bring to a close a years-long fight over access to cystic fibrosis drugs in the U.K., a Parliament committee said it would release on Nov. 30 documents it has...
BioCentury | Jul 27, 2018
Company News

Vertex gives update on CF triple combos

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it expects to submit an NDA by mid-2019 for a triple combination therapy to treat cystic fibrosis. The company is evaluating two different triple combinations -- VX-445 or VX-659 plus...
BioCentury | Jul 25, 2018
Company News

Vertex gives update on CF triple combos, reports earnings

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Wednesday it expects to submit an NDA by mid-2019 for a triple combination therapy to treat cystic fibrosis. The company is evaluating two different triple combinations -- VX-445 or VX-659...
BioCentury | Jul 20, 2018
Company News

NHS makes 'final' offer to Vertex

David Ramsden, chief executive of the U.K.-based Cystic Fibrosis Trust, tweeted out a letter he received from NHS England that detailed what the agency said was its "final proposal" to Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) regarding...
BioCentury | Jul 17, 2018
Company News

Vertex responds to NHS’s ‘final’ offer

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it is evaluating a “final” offer from NHS England for the company’s cystic fibrosis drugs but is concerned the latest bid to break the stalemate between the parties falls short....
BioCentury | Mar 20, 2018
Company News

MPs call on U.K. government to resolve Orkambi impasse

Members of Parliament called on the U.K. government on Monday to resolve an impasse that has stalled reimbursement discussions between Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and NHS England over the price of Orkambi lumacaftor/ivacaftor. The move...
BioCentury | Sep 1, 2014
Strategy

Back to School 2014: Paying the piper

Pharma has lost its pricing power in many countries, as evidenced by reimbursement authorities' willingness to delay or outright deny access to drugs whose costs are deemed unacceptable. Now, the availability of a costly drug...
BioCentury | Feb 11, 2013
Company News

GlaxoSmithKline pharmaceuticals news

...America (PhRMA) said that releasing patient-level trial data is "irresponsible with potentially harmful consequences for future medicine...
Items per page:
1 - 10 of 16